RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration

Journal of Clinical Investigation

Volumn 122, Issue 4, 2012, Pages 1503-1518

  Said, Neveen ^a   Sanchez Carbayo, Marta ^b   Smith, Steven C ^a   Theodorescu, Dan ^c,d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; CLODRONIC ACID; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEOCHONDROITIN SULFATE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO GUANOSINE TRIPHOSPHATASE DISSOCIATION INHIBITOR 2; RS102895; UNCLASSIFIED DRUG; VERSICAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; CANCER PATIENT; CANCER PROGNOSIS; CELL INFILTRATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LUNG METASTASIS; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT;

ANIMALS; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; CHEMOKINE CCL2; CLODRONIC ACID; COCULTURE TECHNIQUES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS; HUMANS; INFLAMMATION; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MACROPHAGES; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PROGNOSIS; PROTEIN ISOFORMS; TUMOR MICROENVIRONMENT; U937 CELLS; URINARY BLADDER NEOPLASMS; VERSICANS;

EID: 84859719825     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI61392     Document Type: Article

References (88)

1. Gildea JJ, et al. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res. 2002;62(22):6418-6423. (Pubitemid 35364098)
2. Theodorescu D, Sapinoso LM, Conaway MR, Oxford G, Hampton GM, Frierson HF Jr. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res. 2004;10(11):3800-3806. (Pubitemid 38697615)
3. Wu Y, Siadaty MS, Berens ME, Hampton GM, Theodorescu D. Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration. Oncogene. 2008;27(52):6679-6689.
4. Dours-Zimmermann MT, Maurer K, Rauch U, Stoffel W, Fassler R, Zimmermann DR. Versican V2 assembles the extracellular matrix surrounding the nodes of ranvier in the CNS. J Neurosci. 2009; 29(24):7731-7742.
5. Dours-Zimmermann MT, Zimmermann DR. A novel glycosaminoglycan attachment domain identified in two alternative splice variants of human versican. J Biol Chem. 1994;269(52):32992-32998.
6. Dutt S, Cassoly E, Dours-Zimmermann MT, Matasci M, Stoeckli ET, Zimmermann DR. Versican V0 and V1 direct the growth of peripheral axons in the developing chick hindlimb. J Neurosci. 2011;31(14):5262-5270.
7. Dutt S, Kleber M, Matasci M, Sommer L, Zimmermann DR. Versican V0 and V1 guide migratory neural crest cells. J Biol Chem. 2006;281(17):12123-12131. (Pubitemid 43855476)
8. Zimmermann DR, Dours-Zimmermann MT. Extracellular matrix of the central nervous system: from neglect to challenge. Histochem Cell Biol. 2008; 130(4):635-653.
9. Asplund A, et al. Hypoxic regulation of secreted proteoglycans in macrophages. Glycobiology. 2010; 20(1):33-40.
10. Seidelmann SB, et al. Athsq1 is an atherosclerosis modifier locus with dramatic effects on lesion area and prominent accumulation of versican. Arterioscler Thromb Vasc Biol. 2008;28(12):2180-2186.
11. Wagsater D, et al. ADAMTS-4 and -8 are inflammatory regulated enzymes expressed in macrophagerich areas of human atherosclerotic plaques. Atherosclerosis. 2008;196(2):514-522.
12. Wilson P, Drennon K, Tannock LR. Regulation of vascular proteoglycan synthesis by metabolic factors associated with diabetes. J Investig Med. 2007; 55(1):18-25. (Pubitemid 46512738)
13. Beck AH, Espinosa I, Gilks CB, van de Rijn M, West RB. The fibromatosis signature defines a robust stromal response in breast carcinoma. Lab Invest. 2008; 88(6):591-601. (Pubitemid 351733278)
14. Brown LF, et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res. 1999; 5(5):1041-1056. (Pubitemid 29233218)
15. Castronovo V, et al. Identification of specific reachable molecular targets in human breast cancer using a versatile ex vivo proteomic method. Proteomics. 2007;7(8):1188-1196. (Pubitemid 46716046)
16. Kischel P, et al. Versican overexpression in human breast cancer lesions: known and new isoforms for stromal tumor targeting. Int J Cancer. 2010; 126(3):640-650.
17. Koyama H, et al. Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment: possible involvement of versican/PG-M. Am J Pathol. 2007; 170(3):1086-1099. (Pubitemid 47339375)
18. Makatsori E, et al. Large matrix proteoglycans, versican and perlecan, are expressed and secreted by human leukemic monocytes. Anticancer Res. 2003;23(4):3303-3309. (Pubitemid 36975427)
19. Read JT, Rahmani M, Boroomand S, Allahverdian S, McManus BM, Rennie PS. Androgen receptor regulation of the versican gene through an androgen response element in the proximal promoter. J Biol Chem. 2007;282(44):31954-31963. (Pubitemid 350106418)
20. Ricciardelli C, et al. Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin Cancer Res. 2002; 8(4):1054-1060. (Pubitemid 35177355)
21. Serra M, et al. V3 versican isoform expression alters the phenotype of melanoma cells and their tumorigenic potential. Int J Cancer. 2005;114(6):879-886.
22. Suwiwat S, et al. Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res. 2004;10(7):2491-2498. (Pubitemid 38445711)
23. Yee AJ, et al. The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis. Breast Cancer Res. 2007;9(4):R47.
24. Yoon H, et al. Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53. Proc Natl Acad Sci U S A. 2002;99(24):15632-15637. (Pubitemid 35403983)
25. Wu Y, McRoberts K, Berr SS, Frierson HF Jr, Conaway M, Theodorescu D. Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia. Oncogene. 2007;26(5):765-773. (Pubitemid 46204255)
26. Chiodoni C, Colombo MP, Sangaletti S. Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. Cancer Metastasis Rev. 2010;29(2):295-307.
27. Rahmani M, et al. Versican: signaling to transcriptional control pathways. Can J Physiol Pharmacol. 2006;84(1):77-92. (Pubitemid 44011953)
28. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol. 2008;66(1):1-9. (Pubitemid 351324128)
29. Wight TN. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol. 2002;14(5):617-623. (Pubitemid 35247746)
30. Bhardwaj A, Frankel WL, Pellegata NS, Wen P, Prasad ML. Intracellular versican expression in mesenchymal spindle cell tumors contrasts with extracellular expression in epithelial and other tumors - a tissue microarray-based study. Appl Immunohistochem Mol Morphol. 2008;16(3):263-266. (Pubitemid 351589549)
31. Bouterfa H, Darlapp AR, Klein E, Pietsch T, Roosen K, Tonn JC. Expression of different extracellular matrix components in human brain tumor and melanoma cells in respect to variant culture conditions. J Neurooncol. 1999;44(1):23-33. (Pubitemid 29515646)
32. de Kluijver J, et al. Bronchial matrix and inflammation respond to inhaled steroids despite ongoing allergen exposure in asthma. Clin Exp Allergy. 2005;35(10):1361-1369.
33. Delpech B, et al. The origin of hyaluronectin in human tumors. Int J Cancer. 1997;72(6):942-948. (Pubitemid 27433555)
34. Docampo MJ, Rabanal RM, Miquel-Serra L, Hernandez D, Domenzain C, Bassols A. Altered expression of versican and hyaluronan in melanocytic tumors of dogs. Am J Vet Res. 2007;68(12):1376-1385. (Pubitemid 350267969)
35. Domenzain C, Docampo MJ, Serra M, Miquel L, Bassols A. Differential expression of versican isoforms is a component of the human melanoma cell differentiation process. Biochim Biophys Acta. 2003; 1642(1-2):107-114. (Pubitemid 37338284)
36. Domenzain-Reyna C, et al. Structure and regulation of the versican promoter: the versican promoter is regulated by AP-1 and TCF transcription factors in invasive human melanoma cells. J Biol Chem. 2009;284(18):12306-12317.
37. Touab M, Villena J, Barranco C, Arumi-Uria M, Bassols A. Versican is differentially expressed in human melanoma and may play a role in tumor development. Am J Pathol. 2002;160(2):549-557.
38. Rahmani M, et al. Regulation of the versican promoter by the beta-catenin-T-cell factor complex in vascular smooth muscle cells. J Biol Chem. 2005; 280(13):13019-13028.
39. Serra M, Pastor J, Domenzain C, Bassols A. Effect of transforming growth factor-beta1, insulin-like growth factor-I, and hepatocyte growth factor on proteoglycan production and regulation in canine melanoma cell lines. Am J Vet Res. 2002;63(8):1151-1158. (Pubitemid 35276901)
40. Smith SC, Theodorescu D. Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer. 2009;9(4):253-264.
41. Steeg PS, Horak CE, Miller KD. Clinical-translational approaches to the Nm23-H1 metastasis suppressor. Clin Cancer Res. 2008;14(16):5006-5012.
42. Moissoglu K, McRoberts KS, Meier JA, Theodorescu D, Schwartz MA. Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases. Cancer Res. 2009; 69(7):2838-2844.
43. Dyrskjot L, et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 2004;64(11):4040-4048. (Pubitemid 38697320)
44. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon- Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol. 2006; 24(5):778-789. (Pubitemid 46622045)
45. Stransky N, et al. Regional copy number-independent deregulation of transcription in cancer. Nat Genet. 2006;38(12):1386-1396. (Pubitemid 44837560)
46. Kim WJ, et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer. 2010;9:3.
47. Dyrskjot L, et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet. 2003;33(1):90-96. (Pubitemid 36068689)
48. Said N, Smith S, Sanchez-Carbayo M, Theodorescu D. Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J Clin Invest. 2011;121(1):132-147.
49. Qian BZ, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222-225.
50. Kim S, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009;457(7225):102-106.
51. Farb A, et al. Extracellular matrix changes in stented human coronary arteries. Circulation. 2004; 110(8):940-947. (Pubitemid 39128619)
52. Lemire JM, Merrilees MJ, Braun KR, Wight TN. Overexpression of the V3 variant of versican alters arterial smooth muscle cell adhesion, migration, and proliferation in vitro. J Cell Physiol. 2002;190(1):38-45.
53. Osada S, Hamada C, Shimaoka T, Kaneko K, Horikoshi S, Tomino Y. Alterations in proteoglycan components and histopathology of the peritoneum in uraemic and peritoneal dialysis (PD) patients. Nephrol Dial Transplant. 2009;24(11):3504-3512.
54. Potter-Perigo S, et al. Poly I:C stimulates versican accumulation in the extracellular matrix promoting monocyte adhesion. Am J Respir Cell Mol Biol. 2010;43(1):109-120.
55. Hagemann T, Robinson SC, Schulz M, Trumper L, Balkwill FR, Binder C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent upregulation of matrix metalloproteases. Carcinogenesis. 2004;25(8):1543-1549. (Pubitemid 39162720)
56. Said N, Socha MJ, Olearczyk JJ, Elmarakby AA, Imig JD, Motamed K. Normalization of the ovarian cancer microenvironment by SPARC. Mol Cancer Res. 2007;5(10):1015-1030. (Pubitemid 350070757)
57. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124(2):263-266. (Pubitemid 43121975)
58. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4(1):71-78. (Pubitemid 38082155)
59. Hagemann T, et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol. 2005;175(2):1197-1205. (Pubitemid 41095008)
60. Mantovani A, Sica A, Allavena P, Garlanda C, Locati M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol. 2009;70(5):325-330.
61. Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR, Wilson JL. The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res. 2005;65(22):10355-10362. (Pubitemid 41743728)
62. Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, Pienta KJ. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem. 2009;284(49):34342-34354.
63. Zhang J, Patel L, Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 2010; 21(1):41-48.
64. Goueffic Y, et al. Sirolimus blocks the accumulation of hyaluronan (HA) by arterial smooth muscle cells and reduces monocyte adhesion to the ECM. Atherosclerosis. 2007;195(1):23-30. (Pubitemid 47561940)
65. Lu X, Kang Y. Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J Biol Chem. 2009;284(42):29087-29096.
66. Piccinini AM, Knebl K, Rek A, Wildner G, Diedrichs- Mohring M, Kungl AJ. Rationally evolving MCP-1/CCL2 into a decoy protein with potent anti-inflammatory activity in vivo. J Biol Chem. 2010; 285(12):8782-8792.
67. Wisniewski T, et al. Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist. J Immunol Methods. 2010;352(1-2):101-110.
68. Said N, Theodorescu D. Pathways of metastasis suppression in bladder cancer. Cancer Metastasis Rev. 2009;28(3-4):327-333.
69. Witz IP. Tumor-microenvironment interactions: dangerous liaisons. Adv Cancer Res. 2008;100:203-229. (Pubitemid 351932184)
70. Mantovani A. Cancer: Inflaming metastasis. Nature. 2009;457(7225):36-37.
71. Miquel-Serra L, et al. V3 versican isoform expression has a dual role in human melanoma tumor growth and metastasis. Lab Invest. 2006;86(9):889-901. (Pubitemid 44268164)
72. Loberg RD, et al. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia. 2006;8(7):578-586. (Pubitemid 44061313)
73. Loberg RD, et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res. 2007; 67(19):9417-9424. (Pubitemid 47535932)
74. Rozel S, et al. Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model. J Cell Biochem. 2009;107(1):58-64.
75. Said NA, Elmarakby AA, Imig JD, Fulton DJ, Motamed K. SPARC ameliorates ovarian cancer-associated inflammation. Neoplasia. 2008;10(10):1092-1104.
76. Zhang J, Lu Y, Pienta KJ. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst. 2010;102(8):522-528.
77. Thompson WL, Van Eldik LJ. Inf lammatory cytokines stimulate the chemokines CCL2/MCP-1 and CCL7/MCP-3 through NFkB and MAPK dependent pathways in rat astrocytes [corrected]. Brain Res. 2009;1287:47-57.
78. Said NA, Najwer I, Socha MJ, Fulton DJ, Mok SC, Motamed K. SPARC inhibits LPA-mediated mesothelial- ovarian cancer cell crosstalk. Neoplasia. 2007;9(1):23-35. (Pubitemid 46203932)
79. Thacker MA, et al. CCL2 is a key mediator of microglia activation in neuropathic pain states. Eur J Pain. 2009;13(3):263-272.
80. Wu Y, et al. Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. Proc Natl Acad Sci U S A. 2009;106(14):5807-5812.
81. Moon HG, et al. Up-regulation of RhoGDI2 in human breast cancer and its prognostic implications. Cancer Res Treat. 2010;42(3):151-156.
82. Li X, Wang J, Zhang X, Zeng Y, Liang L, Ding Y. Overexpression of RhoGDI2 correlates with tumor progression and poor prognosis in colorectal carcinoma. Ann Surg Oncol. 2012;19(1):145-153.
83. Naso MF, Zimmermann DR, Iozzo RV. Characterization of the complete genomic structure of the human versican gene and functional analysis of its promoter. J Biol Chem. 1994;269(52):32999-33008.
84. Sheng W, Dong H, Lee DY, Lu WY, Yang BB. Versican modulates gap junction intercellular communication. J Cell Physiol. 2007;211(1):213-219. (Pubitemid 46363912)
85. Sheng W, et al. The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis. Mol Biol Cell. 2005;16(3):1330-1340. (Pubitemid 40349568)
86. Mukhopadhyay A, et al. Erosive vitreoretinopathy and wagner disease are caused by intronic mutations in CSPG2/Versican that result in an imbalance of splice variants. Invest Ophthalmol Vis Sci. 2006; 47(8):3565-3572. (Pubitemid 351639725)
87. Orenes-Pinero E, et al. Serum and tissue profiling in bladder cancer combining protein and tissue arrays. J Proteome Res. 2010;9(1):164-173.
88. Ruppen I, et al. Differential protein expression profiling by iTRAQ-two-dimensional LC-MS/MS of human bladder cancer EJ138 cells transfected with the metastasis suppressor KiSS-1 gene. Mol Cell Proteomics. 2010;9(10):2276-2291.